Endo's MorphiDex fails Phase III

ENDP said its MorphiDex combination of morphine with dextromethorphan NMDA receptor antagonist failed to meet the primary endpoint of lower morphine use compared to immediate release morphine in a double-blind U.S. Phase III study of 193 patients with chronic pain. ENDP said it would announce results from two other ongoing Phase III studies of MorphiDex in the fourth quarter. ...